Voveran SR (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) formulated for sustained release, designed to provide continuous therapeutic plasma levels for up to 24 hours. It is specifically indicated for the management of chronic pain and inflammatory conditions, offering a convenient once-daily dosing regimen that enhances patient compliance. By inhibiting prostaglandin synthesis, it effectively reduces pain, swelling, and joint stiffness associated with various musculoskeletal disorders. This extended-release formulation ensures steady drug delivery, minimizing peak-trough fluctuations and supporting long-term symptomatic control.

Features

• Contains diclofenac sodium as the active ingredient in a sustained-release matrix
• Available in 75 mg and 100 mg tablet strengths
• Designed for once-daily oral administration
• Provides consistent plasma concentration over 24 hours
• Film-coated for ease of swallowing and gastric protection
• Manufactured under strict pharmaceutical quality standards

Benefits

• Delivers prolonged analgesic and anti-inflammatory effects, reducing the frequency of dosing
• Helps improve mobility and functional capacity in patients with chronic arthritis
• Minimizes fluctuations in pain control, supporting consistent daily activity
• Enhances treatment adherence through convenient once-daily scheduling
• Effectively manages inflammation, swelling, and stiffness in degenerative joint diseases
• Supports long-term symptomatic management with appropriate medical supervision

Common use

Voveran SR is commonly prescribed for the symptomatic treatment of chronic inflammatory and degenerative forms of rheumatism, including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, and acute gout. It is also used in the management of chronic painful inflammatory conditions of the musculoskeletal system, such as tendinitis, bursitis, and low back pain. The sustained-release formulation makes it particularly suitable for conditions requiring round-the-clock pain and inflammation control.

Dosage and direction

The recommended dosage for adults is one 75 mg or 100 mg tablet once daily, taken whole with a sufficient amount of fluid, preferably with meals to minimize gastrointestinal discomfort. Tablets should not be chewed, crushed, or divided, as this would compromise the sustained-release properties. Dosage should be individualized based on the severity of symptoms and patient response, with the lowest effective dose used for the shortest duration necessary. Treatment should be periodically reevaluated for ongoing necessity.

Precautions

Patients should be advised to take Voveran SR at the first sign of pain or inflammation for optimal effectiveness. Use with caution in elderly patients, those with a history of gastrointestinal disorders, hypertension, cardiac impairment, renal or hepatic dysfunction, and bleeding diatheses. Patients should avoid alcohol consumption during treatment due to increased risk of gastrointestinal bleeding. Regular monitoring of renal function, liver enzymes, and blood pressure is recommended during prolonged therapy.

Contraindications

Voveran SR is contraindicated in patients with known hypersensitivity to diclofenac, other NSAIDs, or any components of the formulation. It should not be used in patients with active peptic ulceration, gastrointestinal bleeding, severe cardiac failure, hepatic failure, renal failure, or during the third trimester of pregnancy. It is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.

Possible side effects

Common side effects include gastrointestinal disturbances such as nausea, vomiting, dyspepsia, abdominal pain, diarrhea, and flatulence. Other reported effects include headache, dizziness, skin rash, and peripheral edema. Serious but less frequent adverse reactions may include gastrointestinal ulceration or bleeding, hepatotoxicity, hypertension, fluid retention, heart failure, renal impairment, and severe skin reactions. Patients should discontinue use and seek immediate medical attention if signs of allergic reactions or serious adverse events occur.

Drug interaction

Voveran SR may interact with anticoagulants (increased bleeding risk), other NSAIDs or corticosteroids (increased gastrointestinal toxicity), antihypertensive agents (reduced antihypertensive effect), diuretics (risk of renal impairment), lithium (increased lithium levels), methotrexate (increased methotrexate toxicity), and cyclosporine (increased nephrotoxicity). Concurrent use with SSRIs or antiplatelet agents may increase bleeding risk. Healthcare providers should review all medications before prescribing.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining a consistent dosing time each day helps prevent missed doses and ensures optimal therapeutic levels.

Overdose

Symptoms of overdose may include nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, tinnitus, convulsions, or coma. Respiratory depression and acute renal failure may occur in severe cases. There is no specific antidote; treatment is supportive and symptomatic. Gastric lavage and activated charcoal may be considered if ingestion was recent. Hemodialysis is not effective due to high protein binding.

Storage

Store at room temperature (15-30°C) in a dry place, protected from light and moisture. Keep in the original container with the lid tightly closed. Do not store in bathrooms or other humid areas. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Do not initiate, discontinue, or change dosage without medical supervision. The prescribing physician should be aware of the patient’s complete medical history and concurrent medications.

Reviews

Clinical studies have demonstrated the efficacy of Voveran SR in managing chronic inflammatory pain conditions, with patients reporting significant improvement in pain scores and functional status. Many rheumatologists note its favorable pharmacokinetic profile for sustained pain management. Some patients report gastrointestinal tolerability concerns with long-term use, emphasizing the need for proper patient selection and monitoring. Overall, it is considered a valuable option in the NSAID class for appropriate patients requiring continuous anti-inflammatory therapy.